Royce & Associates’s Palvella Therapeutics PVLA Stock Holding History

Royce & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.19M	Buy	40,509 +9,002	+29%	+$1.09M	0.05%	471
2026 Q1	$3.93M	Buy	31,507 +1,497	+5%	+$156K	0.04%	497
2025 Q4	$3.14M	Sell	30,010 -19,499	-39%	-$1.66M	0.03%	538
2025 Q3	$3.1M	Sell	49,509 -25,007	-34%	-$1.12M	0.03%	539
2025 Q2	$1.68M	Buy	74,516 +3,002	+4%	+$70.5K	0.02%	619
2025 Q1	$2M	Buy	+71,514	New	+$1.38M	0.02%	586
2018 Q4	–	Sell	-39	Closed	-$18K	–	1207
2018 Q3	$18K	Buy	39 +17	+77%	+$7.39K	﹤0.01%	1159
2018 Q2	$9K	Buy	22 +15	+214%	+$7.14K	﹤0.01%	1206
2018 Q1	$4K	Sell	7 -2	-22%	-$1.24K	﹤0.01%	1247
2017 Q4	$6K	Buy	+9	New	+$4.18K	﹤0.01%	1232

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Royce & Associates's PVLA Position: Q2 2026 in Review

Royce & Associates increased its Palvella Therapeutics (PVLA) stake by 29% in Q2 2026, buying an estimated $1.09M and bringing the position to 40,509 shares worth $6.19M. The position accounts for 0.05% of the portfolio, ranked #471.

Royce & Associates first reported a position in PVLA in Q4 2017 and has held it in 10 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Royce & Associates held 40,509 shares of Palvella Therapeutics worth $6.19M as of Q2 2026.
Royce & Associates bought 9,002 Palvella Therapeutics shares in Q2 2026, an estimated $1.09M.
Palvella Therapeutics made up 0.05% of Royce & Associates's portfolio in Q2 2026, its #471 holding.
Royce & Associates first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 10 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.